Scilex Holding Co
SCLX · XNASCIK 1820190fmd_17CW1R65CCX842XTNR04FX8MMEManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2026, 25 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 24 | 31 | 38 | 47 | 57 | 30 |
| Cost of revenue | 2 | 4 | 11 | 16 | 17 | 11 |
| Gross profit | 21 | 28 | 27 | 31 | 167 | 126 |
| Realized investment gains (losses) | – | – | – | – | 0 | 19 |
| Research and development | 10 | 9 | 9 | 13 | 10 | 21 |
| Selling, general and administrative | 43 | 51 | 65 | 120 | 119 | 267 |
| Operating income | (35) | (36) | (51) | (105) | (83) | (346) |
| Interest expense | 13 | 12 | 10 | 1 | 2 | 11 |
| Other non-operating income (expense) | (12) | (53) | 27 | (9) | 11 | (28) |
| Income before taxes | (48) | (88) | (23) | (114) | (73) | (374) |
| Income tax expense | (0) | 0 | 0 | 0 | (0) | 0 |
| Net income from continuing operations | (48) | (88) | (23) | (114) | (73) | (374) |
| Net income | (48) | (88) | (23) | (114) | (73) | (374) |
| Net income to common shareholders | (48) | (88) | (23) | (167) | (73) | (402) |